AAAbdihamid Hirsi Abdulle

Abdihamid Hirsi Abdulle

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abdihamid Hirsi Abdulle has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Oral PCSK9 Inhibition in the Injectable Era: Repositioning Intensive LDL-Cholesterol Lowering in Contemporary Cardiovascular Prevention

    by Abdihamid Hirsi Abdulle, Deka Ahmed Abdi, Omar Adan Bulhan, Ayaan Axmed Maxamed, Abdullahi Abdi Yusuf, Khalid Hussein Ulusow, Salma Mohamed Ahmed, Ayan Mohamed Hassan, Maaida Cabdullaahi Ahmed

  • Open Access

    Regional Cardiac Pacing: Clarifying Learning‐Curve and Benchmarking Evidence

    by Muhammad Safwan, Saman Naz, Abdihamid Hirsi Abdulle

  • Open Access

    Procalcitonin as a Stewardship Checkpoint, Not an Antibiotic Gatekeeper: From Antibiotic Initiation to Discontinuation in Resource-Limited Hospitals

    by Deka Ahmed Abdi, Abdullahi Abdi Yusuf, Aden Mohamed Hirsi, Ayan Mohamed Hassan, Ayan Ahmed Mohamed, Khalid Hussein Ulusow, Abdihamid Hirsi Abdulle, Mohamed Mustaf Ahmed

    Procalcitonin has emerged as a promising biomarker for antimicrobial stewardship; however, its clinical value differs substantially across the antibiotic treatment pathways. Evidence supporting its use to determine whether antibiotics should be initiated remains limited, particularly in patients with suspected sepsis or physiological instability, in whom a low initial concentration cannot safely exclude serious bacterial infections. Its more consistent value appears after empirical treatment has begun, when serial measurements can support clinical reassessment, de-escalation, shorter treatment duration, and earlier discontinuation of treatment. Nevertheless, procalcitonin thresholds and trends should function as decision-support criteria rather than automatic prescribing rules and must be interpreted alongside clinical trajectory, microbiological findings, imaging, organ recovery, infection type, and adequacy of source control. The implementation of this strategy presents additional challenges in resource-limited hospitals, where test availability, turnaround time, repeated measurement, affordability, clinician adherence, and formal stewardship capacity may be inconsistent. Therefore, introducing procalcitonin as an isolated laboratory test may increase expenditure without meaningfully changing antibiotic use. This Perspective proposes selective procalcitonin use among patients already receiving empirical antibiotics whose need for continued treatment remains uncertain, particularly where timely serial testing and structured 24– 72-hour antibiotic review is feasible. In the absence of these conditions, strengthening basic stewardship practices may provide greater value. Therefore, procalcitonin should function as a targeted checkpoint for reassessment and discontinuation rather than as an independent gatekeeper for antibiotic initiation. Plain Language Summary: Procalcitonin is a blood test that may help doctors decide how long a patient needs to be on antibiotics. However, doctors should not use it alone to decide whether to start antibiotics in patients with suspected sepsis because a low result cannot safely rule out a serious bacterial infection. Procalcitonin appears to be more useful after the initiation of treatment. Doctors can use repeated measurements together with the patient’s clinical improvement, laboratory findings, imaging, and control of the infection source to help decide whether antibiotics can be stopped earlier. Resource-limited hospitals may find this approach difficult to implement. Hospitals need affordable testing, rapid results, access to repeat measurements, and regular antibiotic review so that clinicians can act on the findings. Introducing the test without these systems may increase costs without reducing antibiotic use. Resource-limited hospitals should therefore use procalcitonin selectively for patients already receiving empirical antibiotics when clinicians remain uncertain about the need for continued treatment. Where hospitals cannot provide timely repeat testing and structured antibiotic review, strengthening basic antimicrobial stewardship practices should remain the priority.

  • Open Access

    Detecting diphtheria is not enough: the missing toxigenicity link in outbreak surveillance

    by Khalid Hussein Ulusow, Abdimalik Ahmed Bashir, Iqra Abdirazak Kabayare, Maaida Cabdullaahi Ahmed, Abdihamid Hirsi Abdulle

  • Open Access

    Acute Kidney Injury in East Africa in an Era of Converging Renal Stressors: A Multiple‐Hit Narrative Review

    by Abdullahi Abdi Yusuf, Deka Ahmed Abdi, Ayan Mohamed Hassan, Aden Mohamed Hirsi, Iqra Abdirazak Kabayare, Ayan Ahmed Mohomed, Abdihamid Hirsi Abdulle, Khalid Hussein Ulusow

    Background: Acute kidney injury (AKI) remains an important cause of morbidity and mortality in East Africa, where infectious disease, volume depletion, hemodynamic instability, and nephrotoxic exposure frequently occur in resource‐constrained clinical settings. This review aimed to synthesize regional evidence through a multiple‐hit framework focused on three modifiable renal stressor domains. Methods: A structured narrative review of PubMed, Embase, and Scopus was conducted for peer‐reviewed human studies published from January 2012 to 18 August 2026 across the 18 Eastern African countries defined by the United Nations M49 framework. Eligible studies examined AKI in relation to volume depletion or hemodynamic compromise, infection or inflammatory illness, and/or nephrotoxic exposure. Results: Of 902 records identified, 420 duplicates were removed, 482 records were screened, 66 full‐text reports were assessed, and 45 studies were included. Evidence originated from only six countries: Ethiopia, Uganda, Tanzania, Kenya, Somalia/Somaliland, and Rwanda. Across adult, pediatric, neonatal, obstetric, infectious‐disease, emergency, cardiac, and critical‐care populations, AKI was associated with dehydration, hemorrhage, hypotension, shock, malaria, sepsis and other infections, nephrotoxic medications, iodinated contrast, and traditional or herbal medicines. The most consistently documented pattern was cohort‐level clustering of more than one renal stressor domain within the same clinical populations. Individual‐level coexistence was documented in selected studies, whereas detailed temporal sequencing was uncommon. Most studies assessed exposures separately and rarely examined cumulative effects, exposure timing, or statistical interaction. Conclusion: The currently available evidence from East Africa supports a multiple‐hit perspective as a clinical organizing framework rather than a proven biological or prognostic model. Because the evidence is geographically concentrated, particularly in Ethiopia, Uganda, and Tanzania, these findings should not be interpreted as representative of all East African settings. Recurrent cohort‐level clustering of infectious or inflammatory, hemodynamic, and nephrotoxic stressors was well documented, but patient‐level coexistence and temporal sequence remain incompletely characterized. Prospective multicountry studies with patient‐level temporal data are needed to determine whether the timing, overlap, duration, or combination of these stressors influences AKI severity, recovery, and longer‐term outcomes.